We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > SITC

News List

Alector to Present New Data from Multiple Pipeline Programs at 2021 CTAD Conference and SITC Annual Meeting FirstWordPharma
November 04, 2021
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations at the 14th Clinical Trials on Alzheimer's Disease (CTAD) conference...
I-Mab Announces Preclinical Data on Differentiated Anti-C5aR Antibody TJ210/MOR210 at SITC 2020 prnasia
November 12, 2020
I-Mab announced new preclinical data from in vivo and in vitro studies of its C5aR antibody project, TJ210/MOR210, at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
I-Mab Reports Phase 1 Clinical Trial Data of Highly Differentiated Anti-CD47 Monoclonal Antibody Lemzoparlimab at the 2020 SITC Annual Meeting prnasia
November 10, 2020
I-Mab announced initial results from its U.S. phase 1 clinical trial (NCT03934814) evaluating lemzoparlimab (also known as TJC4) for the treatment of relapsed or refractory solid tumors and lymphoma.
Dr Reddy’s presents preclinical data for E7777 (denileukin diftitox) and an immune checkpoint inhibitor at SITC 2020 expresspharma
November 10, 2020
The data reveals significant improvement in tumour growth inhibition and overall survival through a combination of E7777 (Denileukin Diftitox) and an immune checkpoint inhibitor.